Addressing uncertainty in patient selection for transplant in AML
During a meeting of the AML Hub Steering Committee, held on July 22, 2025, Charles Craddock chaired a discussion on the topic: Addressing uncertainty in patient selection for transplant. The discussio...
22 Syys 202523min
Integrating menin inhibitors into the treatment landscape of AML: Future directions
The AML Hub was pleased to speak with Joshua Zeidner, Associate Professor of Medicine at the University of North Carolina Lineberger Comprehensive Cancer Center in Durham, North Carolina. We asked for...
3 Syys 20255min
Know AML webinar | Closing remarks and Q&A
Know AML conducted a healthcare professional (HCP) and patient webinar on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share closing remarks and questions from the...
26 Kesä 20259min
Know AML webinar | How can physicians and patients communicate more clearly about mutation testing in AML going forward?
This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content. Know AML hoste...
19 Kesä 20259min
Know AML webinar | Empowering patients to ask their physician the right questions during their AML journey
Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a discussion between Gail J. Roboz...
13 Kesä 202527min
Know AML webinar | What are mutations, and why do they matter in AML?
Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a presentation by the chair, Charl...
9 Kesä 202513min
“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy
The AML Hub was pleased to speak with Cristina Papayannidis, Universitaria di Bologna, Bologna, IT. We asked, How do you treat a patient with DNMT3A-mutated acute myeloid leukemia (AML) in remission p...
3 Loka 20245min
CPX-351 as first-line treatment in AML: Real-world data
Here, we summarize five real-world studies presented at EHA 2024 on real-world outcomes of patients with AML who received CPX-351 as a first-line treatment. Hosted on Acast. See acast.com/privacy fo...
30 Syys 202416min
